` PRN (Profound Medical Corp) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

PRN
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, PRN has underperformed S&P TSX Composite Index (Canada), delivering a return of -3% compared to the S&P TSX Composite Index (Canada)'s +25% growth.

Stocks Performance
PRN vs S&P TSX Composite Index (Canada)

Loading
PRN
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PRN vs S&P TSX Composite Index (Canada)

Performance Gap Between PRN and GSPTSE
HIDDEN
Show

Performance By Year
PRN vs S&P TSX Composite Index (Canada)

Loading
PRN
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Profound Medical Corp vs Peers

S&P TSX Composite Index (Canada)
PRN
ABT
ISRG
BSX
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Profound Medical Corp
Glance View

Market Cap
301m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
HIDDEN
Show
Back to Top